Chronic Kidney Disease Stage 2
11
1
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
The Effect of Vitamin D3 Supplementation on Hepcidin and Ferritin Serum Levels in Children With Chronic Kidney Disease
Preserving Kidney Function in Children With Chronic Kidney Disease
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
Prospective Decision Impact Trial of KidneyIntelX
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
Application of Wearable Devices to Build a Self-Management Model in Chronic Kidney Disease Patients
Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2
N-Acetyl Cystein and Contrast Nephropathy